This Combined Synopsis/Solicitation opportunity from Department Of Defense was posted on May 26, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Cap-dependent endonuclease inhibitors (CENis) - NHRC
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract focuses on the preclinical development of cap-dependent endonuclease inhibitors (CENis), a class of small molecule antiviral therapeutics aimed at broad-spectrum activity. Activities under this project include lead candidate selection, in vitro and in vivo efficacy testing, and the characterization and optimization of these compounds. An essential component involves research support for preclinical studies of CENis against viruses necessitating biosafety level 4 (BSL-4) containment, with specific support directed to the Naval Medical Research Command located in Fort Detrick, Maryland. The overall duration of the contract is set for 36 months. Issued by the Department of Defense through the Navsup Fleet Logistics Center Norfolk, the contract is identified under solicitation number N0018926QB059 and was posted in May 2026, with a response deadline later that same month. The work is to be performed primarily in Galveston, Texas. The contract does not have any set-aside requirements and falls under the NAICS code 541715, which relates to research and development services. Key contacts for the contract are Brian Kinkade and Jacob Gephart, reachable via their provided email addresses and phone numbers.
General Info
Agency
NAICS
Place of Performance
Galveston, TX, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The preclinical development of Cap-dependent endonuclease inhibitors (CENi), a class of small molecules, as broad-spectrum antiviral therapeutics. The scope of this project includes all activities required to select lead CENi candidates, including in vitro and in vivo efficacy studies and characterization and optimization of lead compounds. This includes Research Support expertise regarding the preclinical development of cap-dependent endonuclease inhibitors (CENis) with viruses that require biosafety level 4 (BSL-4) containment to support the Naval Medical Research Command in Fort Detrick, MD. This work will be performed over a 36-month period.
